Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (47)	2/1/1999 5:16:00 AM
From: CPAMarty	Read Replies (1) \| Respond to of 423

LW, FWIW here are some links to info on cancer research 128.135.138.124 the CNN/Time story on ONXX was very interesting, did you see it?

To: BRAVEHEART who wrote (47)	2/2/1999 7:52:00 AM
From: BRAVEHEART	Read Replies (1) \| Respond to of 423

ISIS 2302 & 3521... Hi Brian, I checked my resources. At this point I stand corrected. Thank you. The only issue I found relative to side effects were lowered platelet counts and dose related bleeding with one patient in the P-1 ISIS 3521 study ( certainly not a serious issue ). I thought for certain the ISIS 2302 product also had bleeding as a side effect. There is a gap in my info. There is no discussion of side effects on ISIS 2302. Was it a release I no longer have access to. the Web site only goes back so far. Was it in a conversation with the company. I am not certain. Clearly if I were still holding ISIP I would make a call to relearn the side-effect profile of 2302. To deliniate for certain if bleeding was an issue. At this point I am assuming I was mistaken. Thank you for questioning me on this matter. I wish I could put it to rest. If and when you determine this beyond a reasonable doubt could you update us. Thank You Jeffrey